Back to Results
First PageMeta Content
Kidney cancer / Organofluorides / Pyridines / Treatment and prognosis of renal cell carcinoma / Sorafenib / Renal cell carcinoma / Sunitinib / Hepatocellular carcinoma / Protein kinase inhibitor / Chemistry / Organic chemistry / Medicine


Microsoft WordSorafenib NEXAVAR BayerPSD FINAL.doc
Add to Reading List

Document Date: 2014-10-01 21:56:23

Open Document

File Size: 38,13 KB

Share Result on Facebook

Company

Sponsor’s Comment Bayer Australia Limited / New England Journal / Bayer Australia Limited / /

Continent

North America / /

Country

Australia / /

Currency

USD / /

Facility

National Cancer Institute / Memorial Sloan Kettering Cancer Centre / /

IndustryTerm

Cancer Therapeutics / literature search / magnetic resonance imaging pharmacodynamic biomarker study / /

MedicalCondition

hypertension / JE / Cancer / brain metastases / disease / IV clear cell renal cell carcinoma / advanced clear-cell renal-cell carcinoma / hepatocellular carcinoma / Progressive disease / advanced clear-cell renal cell carcinoma / diabetes / alopecia / bone metastases / metastatic renal carcinoma / target lesions Stable disease / renal cancer / metastatic renal cancer / renal cell carcinoma / pruritus / advanced renal cell carcinoma / rash / variant renal cell carcinoma / IV clear cell renal carcinoma / /

Organization

National Cancer Institute / World Health Organization / Memorial Sloan Kettering Cancer Centre / American Society of Clinical Oncology / Listing Requested and PBAC’s View Authority / /

Position

Trial ID/First author / /

Product

Nexavar / Sorafenib / /

PublishedMedium

New England Journal of Medicine / Cancer Research / Journal of Clinical Oncology / /

Technology

alpha / magnetic resonance imaging / ultrasound / /

SocialTag